Work

Adjuvant androgen deprivation (ADT) versus mitoxantrone plus prednisone (MP) plus ADT in high-risk prostate cancer (PCa) patients following radical prostatectomy: A phase III intergroup trial (SWOG S9921) NCT00004124.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.6_suppl.2.2017.1.test

Authors: L. Michael Glode, Catherine M. Tangen, Maha Hussain, Gregory P. Swanson, David Peter Wood, Wael Sakr, Nancy Ann Dawson, Naomi B. Haas, Thomas W. Flaig, Tanya B. Dorff, Daniel W. Lin, E. David Crawford, David I. Quinn, Nicholas J. Vogelzang, Ian Murchie Thompson

Institutions: University of Colorado Denver, Fred Hutch Cancer Center, Northwestern University, The University of Texas at San Antonio Health Science Center, Wayne State University, Georgetown Lombardi Comprehensive Cancer Center, Abramson Cancer Center, University of Pennsylvania, University of Colorado Cancer Center, University of Southern California, University of Washington, USC Norris Comprehensive Cancer Center, Comprehensive Cancer Centers of Nevada

Language: English

Topic: Prostate Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4251118216

Cites:

Cited by: 5

Related to: 10